87 related articles for article (PubMed ID: 10597265)
1. BRCA1 signals ARF-dependent stabilization and coactivation of p53.
Somasundaram K; MacLachlan TK; Burns TF; Sgagias M; Cowan KH; Weber BL; el-Deiry WS
Oncogene; 1999 Nov; 18(47):6605-14. PubMed ID: 10597265
[TBL] [Abstract][Full Text] [Related]
2. The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoter.
Chai YL; Cui J; Shao N; Shyam E; Reddy P; Rao VN
Oncogene; 1999 Jan; 18(1):263-8. PubMed ID: 9926942
[TBL] [Abstract][Full Text] [Related]
3. BRCA1 physically associates with p53 and stimulates its transcriptional activity.
Zhang H; Somasundaram K; Peng Y; Tian H; Zhang H; Bi D; Weber BL; El-Deiry WS
Oncogene; 1998 Apr; 16(13):1713-21. PubMed ID: 9582019
[TBL] [Abstract][Full Text] [Related]
4. BRCA1 carries tumor suppressor activity distinct from that of p53 and p21.
Randrianarison V; Marot D; Foray N; Cabannes J; Méret V; Connault E; Vitrat N; Opolon P; Perricaudet M; Feunteun J
Cancer Gene Ther; 2001 Oct; 8(10):759-70. PubMed ID: 11687899
[TBL] [Abstract][Full Text] [Related]
5. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
6. Topoisomerase IIalpha mediates E2F-1-induced chemosensitivity and is a target for p53-mediated transcriptional repression.
Nip J; Hiebert SW
Cell Biochem Biophys; 2000; 33(2):199-207. PubMed ID: 11325040
[TBL] [Abstract][Full Text] [Related]
7. Transactivation of the p21 promoter by BRCA1 splice variants in mammary epithelial cells: evidence for both common and distinct activities of wildtype and mutant forms.
Lu M; Arrick BA
Oncogene; 2000 Dec; 19(54):6351-60. PubMed ID: 11175350
[TBL] [Abstract][Full Text] [Related]
8. Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation.
Hakem R; de la Pompa JL; Elia A; Potter J; Mak TW
Nat Genet; 1997 Jul; 16(3):298-302. PubMed ID: 9207798
[TBL] [Abstract][Full Text] [Related]
9. Functional and physical interactions between BRCA1 and p53 in transcriptional regulation of the IGF-IR gene.
Abramovitch S; Werner H
Horm Metab Res; 2003; 35(11-12):758-62. PubMed ID: 14710355
[TBL] [Abstract][Full Text] [Related]
10. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage.
Seoane J; Le HV; Massagué J
Nature; 2002 Oct; 419(6908):729-34. PubMed ID: 12384701
[TBL] [Abstract][Full Text] [Related]
11. ING1 represses transcription by direct DNA binding and through effects on p53.
Kataoka H; Bonnefin P; Vieyra D; Feng X; Hara Y; Miura Y; Joh T; Nakabayashi H; Vaziri H; Harris CC; Riabowol K
Cancer Res; 2003 Sep; 63(18):5785-92. PubMed ID: 14522900
[TBL] [Abstract][Full Text] [Related]
12. p53 is a NF-Y- and p21-independent, Sp1-dependent repressor of cyclin B1 transcription.
Innocente SA; Lee JM
FEBS Lett; 2005 Feb; 579(5):1001-7. PubMed ID: 15710382
[TBL] [Abstract][Full Text] [Related]
13. A novel domain of BRCA1 interacts with p53 in breast cancer cells.
Buck M
Cancer Lett; 2008 Sep; 268(1):137-45. PubMed ID: 18501503
[TBL] [Abstract][Full Text] [Related]
14. Effects of topoisomerase II inhibitors on gastric cancer cells characterized by different genetic lesions.
Scovassi AL; Pellegata NS; Di Stefano L; Padovan L; Negri C; Prosperi E; Riva F; Ciomei M; Ranzani GN
Anticancer Res; 2001; 21(4A):2803-8. PubMed ID: 11724358
[TBL] [Abstract][Full Text] [Related]
15. DNA topoisomerase II inhibitor, etoposide, induces p21WAF1/CIP1 through down-regulation of c-Myc in K562 cells.
Horiguchi-Yamada J; Fukumi S; Saito S; Nakayama R; Iwase S; Yamada H
Anticancer Res; 2002; 22(6C):3827-32. PubMed ID: 12553001
[TBL] [Abstract][Full Text] [Related]
16. Epstein-barr virus nuclear antigen 2 retards cell growth, induces p21(WAF1) expression, and modulates p53 activity post-translationally.
Lin CS; Kuo HH; Chen JY; Yang CS; Wang WB
J Mol Biol; 2000 Oct; 303(1):7-23. PubMed ID: 11021966
[TBL] [Abstract][Full Text] [Related]
17. Dysfunction of the p53 tumor suppressor pathway in head and neck cancer.
Hoque MO; Kawamata H; Nakashiro K; Omotehara F; Hino S; Uchida D; Harada K; Begum NM; Yoshida H; Sato M; Fujimori T
Int J Oncol; 2002 Jul; 21(1):119-26. PubMed ID: 12063558
[TBL] [Abstract][Full Text] [Related]
18. Role of an ING1 growth regulator in transcriptional activation and targeted histone acetylation by the NuA4 complex.
Nourani A; Doyon Y; Utley RT; Allard S; Lane WS; Côté J
Mol Cell Biol; 2001 Nov; 21(22):7629-40. PubMed ID: 11604499
[TBL] [Abstract][Full Text] [Related]
19. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
20. Melanoma cells can tolerate high levels of transcriptionally active endogenous p53 but are sensitive to retrovirus-transduced p53.
Kichina JV; Rauth S; Das Gupta TK; Gudkov AV
Oncogene; 2003 Jul; 22(31):4911-7. PubMed ID: 12894234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]